Novo Nordisk Crashes Most On Record After CagriSema GLP-1 Results Disappoint
Novo Nordisk Crashes Most On Record After CagriSema GLP-1 Results Disappoint Novo Nordisk’s top-line efficacy results for its experimental obesity drug, CagriSema, were just released, missing the pharma’s estimate of 25% weight loss over 68 weeks, coming in at just 22.7%. This sent shares of Novo in Europe crashing the most on record. The results: When evaluating the […]
Discuss on Nostr!
Nostr Note ID note1dm5tmdawdpq9qm84mgura6qz04z3p206l44nyzqvxkmy030flmlqrn67m5 Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.